Icon
+91 94997 68112
Login Register

Tirosint - (75, 150 mcg; Capsule, Oral)

Levothyroxine Sodium IBSA
75, 150 mcg; Capsule, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
None None
Indicated as a replacement therapy in adults and pediatric patients 6 years and older with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Yes
**** ** *** ***** ** **** **** ** **** ******* '***, '*** **** ******** ** **** **, **** *** *** ************ *********. ** ****** **** **** **** ******* ** *** ****. **** ***** * **** ** ** **, *** *** ********. (**** **. ******)
Tirosint Patent 1 Patent 2
**** ********* *** ** ** *** **
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ *** *** **, **** *** ** ** *** ** ******** ************ ** *** **, ****
  1. *** **, **** : **** ******** **** ***** *** **** ** **** ******* '***, '*** **** ******** ** **** **, ****
  2. *** **, **** : **** ***** * **** ******* **** ** ******** ***** ** ********.
  3. *** **, **** : **** ******* **** **** ** *** ******.
  4. *** **, **** : ********** ** ********* **** **** *** ****** '***. * ********* ** ****** ** ***** ** **** *** ******* **** **** '***(***** **,****) ****** ** *******, **** ******* ** **
  5. *** **, **** : **** *** ** ** ** *** ******* ******* (**) ********* *** **'* ********.

Tirosint - (88, 100, 125 mcg; Capsule, Oral)

Levothyroxine Sodium IBSA
88, 100, 125 mcg; Capsule, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
None None
TIROSINT is indicated as a replacement therapy in adults and pediatric patients 6 years and older with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Yes
**** ** ******** ***. **** ***** * **** ** ** ******* ******* (***** **, ****), ******* (***** **, ****) *** *** *********. ** ****** **** *** **** **** ****** ** *** ****. **** ***** * **** ** ** **, *** *** *** *** ********.(**** **. ******)
Tirosint Patent 1 Patent 2
**** ********* *** ** ** *** **
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* *** **, **** *** ** ** *** ** ************ ****** **** ********
  1. *** *, **** : * **** ** ** ***** *** ******* ** ******* *** *******
  2. *** **, **** : **** ******** **** ***** **'* **** ** ************* ** ******* ******* (***** **, ****) *** ******* (***** **, ****). **** ***** * **** ** ** **, *** *** *** *** ********
  3. *** *, **** : **** ***** * **** ******* **** ** ******* ******* (***** **, ****) *** ******* (***** **, ****). ** ***** **** ** ******** *** **** ** ******* ** ***** *** ** * ******** **********.
  4. *** *, **** : ********** ******* **** *********** ********* *** **** *** ******* ******** ** ** ** ******* **** ********** ******* ** ********* **** ****** '*** ** *******
  5. *** **, **** : * ********* ** ****** ** ***** ** **** *** ******* **** **** '***(***** **,****) ****** ** *******, **** ******* ** **
  6. *** **, **** : **** *** ** ** ** *** ** ********* **'* ******** ** ********** ** ****** '***.

Tirosint - (200 mcg ; Capsules)

Levothyroxine Sodium IBSA
200 mcg ; Capsules
Less Than $1000 mn
None None
More Than 5
 None
None None
TIROSINT is L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: • Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer
Yes
  1. *** **, **** : * **** ** *** ***** *** ***** ** * *** *******.

Tirosint - (137 and 175 mcg; Capsule)

Levothyroxine Sodium IBSA
137 and 175 mcg; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
 None
Tirosint is used as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, or in the treatment or prevention of various types of euthyroid goiters, as an adjunct to surgery and radioiodine therapy in the management of thyrotripin-dependment well differentiated thyroid cancer.
Yes
Tirosint Patent 1 Patent 2
**** *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** -**- *** ********* ******** ************ ****** **** ********
  1. *** *, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : **** ******** ***** ******** *** *** *** *********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.